Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RYTM 
Rhythm Pharmaceuticals Inc (RYTM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: RYTM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $82.08
Year Target Price $82.08
| 8 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 14.89% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.99B USD | Price to earnings Ratio - | 1Y Target Price 83.42 |
Price to earnings Ratio - | 1Y Target Price 83.42 | ||
Volume (30-day avg) - | Beta 2.3 | 52 Weeks Range 40.46 - 69.89 | Updated Date 06/29/2025 |
52 Weeks Range 40.46 - 69.89 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -123.28% | Operating Margin (TTM) -143.73% |
Management Effectiveness
Return on Assets (TTM) -51.33% | Return on Equity (TTM) -150.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3824055723 | Price to Sales(TTM) 29.16 |
Enterprise Value 3824055723 | Price to Sales(TTM) 29.16 | ||
Enterprise Value to Revenue 27.94 | Enterprise Value to EBITDA -12.65 | Shares Outstanding 63621500 | Shares Floating 51492675 |
Shares Outstanding 63621500 | Shares Floating 51492675 | ||
Percent Insiders 0.67 | Percent Institutions 107.02 |
Analyst Ratings
Rating 4.67 | Target Price 82.08 | Buy 4 | Strong Buy 8 |
Buy 4 | Strong Buy 8 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Rhythm Pharmaceuticals Inc
Company Overview
History and Background
Rhythm Pharmaceuticals Inc. was founded in 2008. It's a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases of obesity.
Core Business Areas
- Obesity Therapeutics: Focuses on developing and commercializing therapeutics for rare genetic diseases of obesity, particularly melanocortin-4 receptor (MC4R) pathway deficiencies.
Leadership and Structure
David Meury is the CEO. The company has a typical biopharmaceutical organizational structure with departments including research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- IMCIVREE (setmelanotide): IMCIVREE is approved for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing and Bardet-Biedl syndrome (BBS). Revenue is primarily from IMCIVREE sales. Competitors are companies developing and marketing weight loss drugs such as Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound).
Market Dynamics
Industry Overview
The pharmaceutical industry for obesity therapeutics is growing rapidly, driven by increasing prevalence of obesity and advancements in understanding the underlying genetic and biological mechanisms.
Positioning
Rhythm is positioned as a leader in rare genetic obesity with a focus on MC4R pathway deficiencies, giving them a niche in a large and competitive market. They have first-mover advantage in their specific indications.
Total Addressable Market (TAM)
The global obesity market is estimated to be in the tens of billions of dollars. Rhythm's initial focus on rare genetic obesities represents a smaller, but significant, segment of this market. Rhythm has a large TAM within the rare genetic obesity space, estimated in the hundreds of millions annually, with potential for expansion into broader obesity indications.
Upturn SWOT Analysis
Strengths
- First-mover advantage in rare genetic obesity
- Approved product (IMCIVREE)
- Strong intellectual property position
- Deep understanding of MC4R pathway
Weaknesses
- Reliance on a single product
- Small patient population for approved indications
- Requires genetic testing for diagnosis and treatment
- Limited commercial infrastructure
Opportunities
- Expansion into broader obesity indications
- Development of new therapies targeting MC4R pathway
- Partnerships with larger pharmaceutical companies
- Geographic expansion
Threats
- Competition from larger pharmaceutical companies
- Regulatory challenges
- Reimbursement challenges
- Clinical trial failures
Competitors and Market Share
Key Competitors
- NVO
- LLY
Competitive Landscape
Rhythm's advantage lies in addressing rare genetic causes of obesity. However, Novo Nordisk and Eli Lilly have a broader approach for other obesity treatment. Rhythm needs to expand its addressable target market to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the approval and commercial launch of IMCIVREE.
Future Projections: Future growth is projected to come from increased IMCIVREE sales, potential expansion into new indications, and development of new therapies.
Recent Initiatives: Recent initiatives include expanding the IMCIVREE label, conducting clinical trials for new indications, and strengthening the commercial infrastructure.
Summary
Rhythm Pharmaceuticals is a niche player in the obesity market, targeting rare genetic causes. The company's IMCIVREE product provides a solid revenue stream, but its long-term success depends on expanding its pipeline and addressable market. Competition from major pharmaceutical companies remains a significant challenge. Rhythm's financial performance needs improvement as it is currently unprofitable.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rhythm Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2017-10-05 | Chairman, President & CEO Dr. David P. Meeker M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 283 | Website https://rhythmtx.com |
Full time employees 283 | Website https://rhythmtx.com | ||
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.